Cancer vaccines sales will strengthen through 2036, anchored by recombinant cancer vaccines at 33.9% of the technology segment in 2026. The market was valued at USD 11.38 billion in 2025 and is expected to be worth USD 39.27 billion by 2036, creating an incremental opportunity of USD 26.63 billion.